Robert Zaczek

Neurop, Inc.

$2,835,948

Attributed

$3,917,894

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.2M · FY2017–19

$2.5M$1.9M$1.3M$625K$0

'17

'18

'19

Funding mix

By agency

NIH$3,917,894 · 2

By mechanism

R44$3,616,591 · 1

R41$301,303 · 1

Top collaborators

George Walter Koszalka1 shared

Most similar at Neurop, Inc.

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Sedation Procedure”

Daniel Sing-Kwong Tsze · Columbia University Health Sciences$10,143,894
Chani Traube · Children'S Research Institute$6,104,147
Tuan Le Mau · Pascall Systems, Incorporated$6,057,952
Lawrence C Kuo · Mebias Discovery, Inc.$5,983,188
Joseph A Janicki · Lurie Children'S Hospital Of Chicago$5,541,590
James E. Barrett · Mebias Discovery, Inc.$4,805,544

Research focus

Sedation ProcedureDependencePharmaceutical PreparationsSafetySubarachnoid HemorrhagePreventImpairmentN-Methyl-D-Aspartate ReceptorsPre-ClinicalPropertyDoseBaseBrainBrain IschemiaGlutamatesGrantInhibitor/AntagonistN-MethylaspartateCessation Of LifePhase 1 StudyBrain InjuriesAneurysmClinical DevelopmentDocumentation

Grant awards (4)

Phase 1 Clinical Evaluation of NP10679, a GluN2B Selective, Context-Dependent NMDA Receptor Inhibitor for Subarachnoid Hemorrhage$125,000

R44 · FY2019 · NS · contact PI

Phase 1 Clinical Evaluation of NP10679, a GluN2B Selective, Context-Dependent NMDA Receptor Inhibitor for Subarachnoid Hemorrhage$1,327,699

R44 · FY2018 · NS · contact PI

Preclinical assessment of the GluN2B inhibitor clinical candidate NP10679 as a medication to prevent opiate abuse relapse$301,303

R41 · FY2018 · DA · contact PI

Phase 1 Clinical Evaluation of NP10679, a GluN2B Selective, Context-Dependent NMDA Receptor Inhibitor for Subarachnoid Hemorrhage$2,163,892

R44 · FY2017 · NS · contact PI